Adrenocortical tumors in children: Sri Lankan experience from a single center, and a mini review.
Adrenocortical adenoma
Adrenocortical carcinoma
Paediatric cancer
Journal
Journal of medical case reports
ISSN: 1752-1947
Titre abrégé: J Med Case Rep
Pays: England
ID NLM: 101293382
Informations de publication
Date de publication:
13 Apr 2023
13 Apr 2023
Historique:
received:
06
02
2023
accepted:
14
03
2023
medline:
14
4
2023
entrez:
12
4
2023
pubmed:
13
4
2023
Statut:
epublish
Résumé
Pediatric adrenocortical tumors include both benign adenomas and highly virulent malignant tumors. However, they are very rare among children. The aim of this study is to evaluate the clinicopathological data of children presenting with adrenocortical tumors and assess their survival in a South Asian population. This is a retrospective cohort study that includes patients diagnosed with adrenocortical tumors from August 2020 to August 2022 followed-up at Lady Ridgeway Hospital. Seven children were diagnosed with adrenal cortical tumors. Their ages ranged from 10 months to 6.5 years. Five of them were boys. All displayed signs of peripheral precocious puberty. One boy phenotypically had features of Beckwith-Wiedemann syndrome. The median time for diagnosis after the onset of symptoms was 4.4 months. The preoperative diagnosis was based on clinical manifestations, elevated dehydroepiandrosterone sulfate levels, and suprarenal masses on computed tomography. All five boys had right-sided suprarenal masses, while the two girls had them on the left side. All underwent surgery for tumor resection. The diagnosis was confirmed based on the histopathology of the adrenal specimens. Four children had a Wieneke score of 4 or more, suggesting the possibility of adrenocortical carcinoma; however, only two of them behaved as malignant tumors. To date, two children have developed local recurrences within a very short period. Adrenocortical tumors are uncommon in children, and treatment options are limited. To identify early recurrences, routine clinical, radiological, and biochemical examinations at least once every 6-8 weeks is important.
Sections du résumé
BACKGROUND
BACKGROUND
Pediatric adrenocortical tumors include both benign adenomas and highly virulent malignant tumors. However, they are very rare among children. The aim of this study is to evaluate the clinicopathological data of children presenting with adrenocortical tumors and assess their survival in a South Asian population.
CASE PRESENTATION
METHODS
This is a retrospective cohort study that includes patients diagnosed with adrenocortical tumors from August 2020 to August 2022 followed-up at Lady Ridgeway Hospital. Seven children were diagnosed with adrenal cortical tumors. Their ages ranged from 10 months to 6.5 years. Five of them were boys. All displayed signs of peripheral precocious puberty. One boy phenotypically had features of Beckwith-Wiedemann syndrome. The median time for diagnosis after the onset of symptoms was 4.4 months. The preoperative diagnosis was based on clinical manifestations, elevated dehydroepiandrosterone sulfate levels, and suprarenal masses on computed tomography. All five boys had right-sided suprarenal masses, while the two girls had them on the left side. All underwent surgery for tumor resection. The diagnosis was confirmed based on the histopathology of the adrenal specimens. Four children had a Wieneke score of 4 or more, suggesting the possibility of adrenocortical carcinoma; however, only two of them behaved as malignant tumors. To date, two children have developed local recurrences within a very short period.
CONCLUSION
CONCLUSIONS
Adrenocortical tumors are uncommon in children, and treatment options are limited. To identify early recurrences, routine clinical, radiological, and biochemical examinations at least once every 6-8 weeks is important.
Identifiants
pubmed: 37046342
doi: 10.1186/s13256-023-03890-5
pii: 10.1186/s13256-023-03890-5
pmc: PMC10099899
doi:
Types de publication
Case Reports
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
137Informations de copyright
© 2023. The Author(s).
Références
Pediatr Blood Cancer. 2019 Jun;66(6):e27710
pubmed: 30868719
Front Cell Dev Biol. 2015 Jul 03;3:45
pubmed: 26191527
Pediatr Surg Int. 2019 Mar;35(3):365-371
pubmed: 30392130
Mod Pathol. 2019 Apr;32(4):546-559
pubmed: 30401946
Braz J Med Biol Res. 2000 Oct;33(10):1225-34
pubmed: 11004724
J Clin Oncol. 2004 Mar 1;22(5):838-45
pubmed: 14990639
Front Endocrinol (Lausanne). 2015 Feb 18;6:23
pubmed: 25741319
J Pediatr Endocrinol Metab. 2011;24(7-8):535-41
pubmed: 21932594
Med Pediatr Oncol. 1999 Feb;32(2):106-11
pubmed: 9950198
Front Oncol. 2020 Oct 15;10:554388
pubmed: 33178583
Klin Padiatr. 2012 Oct;224(6):366-71
pubmed: 23143764
J Pediatr Surg. 2001 Apr;36(4):549-54
pubmed: 11283875
Mol Cell Endocrinol. 2012 Mar 31;351(1):37-43
pubmed: 22040600
Best Pract Res Clin Endocrinol Metab. 2020 May;34(3):101448
pubmed: 32636100
Indian J Endocrinol Metab. 2012 May;16(3):431-5
pubmed: 22629514
Pediatr Blood Cancer. 2005 Sep;45(3):265-73
pubmed: 15747338
J Pediatr Surg. 2011 Jun;46(6):1201-7
pubmed: 21683223
Eur Endocrinol. 2018 Sep;14(2):62-66
pubmed: 30349596
Horm Res Paediatr. 2018;90(1):8-18
pubmed: 29804118
Pediatr Endocrinol Rev. 2006 Sep;4(1):32-9
pubmed: 17021581
Am J Surg Pathol. 2003 Jul;27(7):867-81
pubmed: 12826878
Eur J Endocrinol. 2018 Oct 01;179(4):G1-G46
pubmed: 30299884